Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 36 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/7/2007 First Published: 2/1/2002


1.		Phase II/III Randomized Study of Docetaxel With or Without Oblimersen (Bcl-2 Antisense Oligonucleotide; G3139 ) in Patients With Previously Treated Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				GENTA-GN304 NCI-G01-2046, UCLA-0301058, NCT00030641

Last Modified: 2/25/2003 First Published: 5/1/2001


2.		Phase III Randomized Study of Dacarbazine With or Without Oblimersen (G3139) in Patients With Advanced Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				Pharmaceutical / Industry				GENTA-GM301 UCLA-0207109, NCT00016263

Last Modified: 8/25/2003 First Published: 6/1/2001


3.		Phase III Randomized Study of Dexamethasone With or Without Oblimersen in Patients With Relapsed or Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				GENTA-GMY302 UF-G-29-2001, NCT00017602

Last Modified: 2/17/2007 First Published: 9/1/2001


4.		Phase III Randomized Study of Fludarabine and Cyclophosphamide With or Without Oblimersen (G3139, Genasense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Over 18				Pharmaceutical / Industry				GENTA-GL303 UCLA-0104008, NCT00024440

Last Modified: 12/18/2006 First Published: 5/28/2004


5.		Phase III Randomized Study of Daunorubicin and Cytarabine With or Without Oblimersen in Older Patients With Previously Untreated Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				60 and over				NCI				CALGB-10201 NCT00085124

Last Modified: 12/1/2001 First Published: 12/1/1997


6.		Phase I/II Study of Oblimersen With Docetaxel in Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumors (Summary Last Modified 12/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				MSKCC-97096 GENTA-G3139-97/01, NCI-G97-1337, NCT00003103

Last Modified: 9/1/2001 First Published: 3/1/2000


7.		Phase I/II Study of Augmerosen and Irinotecan in Patients With Metastatic or Recurrent Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				SACI-IDD-98-32 UTHSC-IDD-98-32, NCI-T98-0094, NCT00004870, T98-0094

Last Modified: 8/21/2007 First Published: 4/1/2000


8.		Phase I/II Study of Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Patients With Recurrent Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				UCCRC-10017 NCI-T98-0091, NCT00005032, T98-0091

Last Modified: 12/18/2002 First Published: 7/1/2001


9.		Phase I/II Study of Oblimersen in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				GENTA-GL208 MDA-ID-00337, NCT00021190

Last Modified: 3/1/2005 First Published: 2/21/2003


10.		Phase I/II Study of Oblimersen, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Patients With Advanced Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				SACI-IDD-02-23 NCI-5793, NCT00055822, 5793

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute